<DOC>
	<DOCNO>NCT00445978</DOCNO>
	<brief_summary>This Phase 2a , multicenter , open-label , dose-escalation study design ass safety biologic activity daily oral administration 4 escalate dos 6R-BH4 16 week subject sickle cell disease . During optional extension phase , study ass safety , tolerability , efficacy extend treatment 6R-BH4 , total 2 year .</brief_summary>
	<brief_title>A Phase 2 Study Effects 6R-BH4 Subjects With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Diagnosis SCD , confirm hemoglobin electrophoresis . At least 15 year age . Dosage medication ( ) use treat cardiac disease , hypertension ( eg , calciumchannel blocker ) , elevate cholesterol , iron overload ( eg , desferoximine ) type 2 diabetes must unchanged least 30 day prior Screening . Willing able provide write , sign informed consent , case subject age 18 year , provide write assent ( require ) write informed consent legally authorize representative nature study explain , prior researchrelated procedure . Willing able comply study procedure . Sexually active subject must willing use acceptable method contraception participate study . Females childbearing potential must negative pregnancy test Screening willing additional pregnancy test study . Females consider childbearing potential include menopausal least 2 year , tubal ligation least 1 year prior Screening , total hysterectomy . Requires chronic hypertransfusion therapy . Sickle cell crisis 30 day prior Screening . Myocardial infarction , cerebral vascular accident , pulmonary embolism 6 month prior Screening . History bone marrow hematopoietic stem cell transplantation . Hepatic dysfunction ( alanine aminotransferase [ ALT ] [ SGPT ] &gt; 2 time upper limit normal [ ULN ] ) . Renal dysfunction serum creatinine &gt; 1.5 mg/dL . On outpatient oxygen therapy , continuous positive airway pressure ( CPAP ) bilevel positive airway pressure ( BiPAP ) therapy . Uncontrolled hypertension ( define blood pressure &gt; 135/85 mm Hg ) Screening . History chronic symptomatic hypotension . Concurrent disease condition would interfere study participation safety , include , limited : bleeding disorder , history syncope vertigo , severe gastroesophageal reflux disease ( GERD ) , arrhythmia , organ transplant , organ failure , type 1 diabetes mellitus ( subject type 2 diabetes allow ) , serious neurological disorder ( include seizure ) . Hydroxyurea therapy 3 month prior Screening anticipate need hydroxyurea course study . Treatment phosphodiesterase ( PDE ) 5 inhibitor ( Viagra® , Cialis® , Levitra® Revatio™ ) , PDE 3 inhibitor ( eg , cilostazol , milrinone , vesnarinone ) , pentoxifylline ( Trental® ) , nitrate/nitritebased vasodilator , bosentan ( Tracleer® ) , Larginine , levodopa , dietary supplement contain Larginine gingko biloba within 30 day prior Screening , anticipate need treatment agent course study . Requirement concomitant treatment drug know inhibit folate metabolism ( eg , methotrexate ) . Previous treatment vascular endothelial growth factor ( VEGF ) VEGF inhibitor . Has know hypersensitivity 6RBH4 excipients . Use investigational product , device , formulation BH4 within 30 day prior Screening , requirement investigational agent prior completion schedule study assessment . Pregnant breastfeed Screening plan become pregnant ( self partner ) time study . Any condition , view Investigator , place subject high risk poor treatment compliance complete study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>SCD</keyword>
	<keyword>6R-BH4</keyword>
	<keyword>BH4</keyword>
	<keyword>sapropterin dihydrochloride</keyword>
	<keyword>endothelial dysfunction</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>NO</keyword>
</DOC>